As gene therapy continues to evolve, overcoming the variability and scaling challenges in AAV manufacturing is crucial for the production of safe and effective treatments. Manufacturers face difficulties in ensuring consistent yields, product quality, and scalability, which are vital for meeting clinical and commercial demands. This article examines the latest strategies and innovations being employed to address these challenges, paving the way for more reliable and scalable AAV production in the gene therapy field.
